Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Chronic Heart Failure

  Free Subscription


Articles published in Eur Heart J

Retrieve available abstracts of 205 articles:
HTML format
Text format



Single Articles


    February 2018
  1. EL HARANE N, Kervadec A, Bellamy V, Pidial L, et al
    Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.
    Eur Heart J. 2018 Feb 6. pii: 4840711. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  2. LAM CSP, Gamble GD, Ling LH, Sim D, et al
    Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
    Eur Heart J. 2018 Jan 29. pii: 4829677. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. NELSON MD, Wei J, Bairey Merz CN
    Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?
    Eur Heart J. 2018 Jan 16. pii: 4811982. doi: 10.1093.
    PubMed     Text format    


  4. HEINZMANN D, Seizer P
    Mitochondria in heart failure: EMID-sign.
    Eur Heart J. 2018 Jan 3. pii: 4786075. doi: 10.1093.
    PubMed     Text format    


  5. LUND LH, Kober L, Swedberg K, Ruschitzka F, et al
    The year in cardiology 2017: heart failure.
    Eur Heart J. 2018 Jan 2. pii: 4774532. doi: 10.1093.
    PubMed     Text format    


  6. LUSCHER TF
    Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation.
    Eur Heart J. 2018;39:1-4.
    PubMed     Text format    


  7. PACKER M
    The Future Treatment of Heart Failure?
    Eur Heart J. 2018;39:5-7.
    PubMed     Text format    


    December 2017
  8. TAQUETI VR, Solomon SD, Shah AM, Desai AS, et al
    Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.
    Eur Heart J. 2017 Dec 26. pii: 4775060. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. ARRIGO M, Vodovar N, Nougue H, Sadoune M, et al
    The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
    Eur Heart J. 2017 Dec 13. pii: 4735305. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. WILCOX JE, Mann DL
    Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?
    Eur Heart J. 2017 Dec 11. pii: 4728646. doi: 10.1093.
    PubMed     Text format    


    November 2017
  11. MASIP J, Peacock WF, Price S, Cullen L, et al
    Indications and practical approach to non-invasive ventilation in acute heart failure.
    Eur Heart J. 2017 Nov 26. pii: 4654494. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. GRASSI G, Mancia G
    'Keep an eye' on the heart: retinal microcirculation disarray in congestive heart failure.
    Eur Heart J. 2017 Nov 23. pii: 4654727. doi: 10.1093.
    PubMed     Text format    


  13. NICHOLLS M
    Finn Waagstein MD PhD: Finn Waagstein reflects on his work and research which saw beta-blockers revolutionise the treatment of heart failure patients. Mark Nicholls reports.
    Eur Heart J. 2017;38:3249-3250.
    PubMed     Text format    


  14. ROSANO GMC
    HFA Congress 2017: The Congress of the Heart Failure Association of the ESC: a continuous success story, the result of a long-term vision.
    Eur Heart J. 2017;38:3042-3043.
    PubMed     Text format    


  15. TOFIELD A
    Heart Failure Congress sets record: The 2017 ESC Heart Failure Association Congress had a new record number of submissions for original science.
    Eur Heart J. 2017;38:3041.
    PubMed     Text format    


    October 2017
  16. NAGELE MP, Barthelmes J, Ludovici V, Cantatore S, et al
    Retinal microvascular dysfunction in heart failure.
    Eur Heart J. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. CLELAND JGF, Bunting KV, Flather MD, Altman DG, et al
    Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
    Eur Heart J. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. LUSCHER TF
    Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles.
    Eur Heart J. 2017;38:2857-2859.
    PubMed     Text format    


  19. BLANTON RM
    What can haemodynamic profiles teach us about heart failure in the paediatric population?
    Eur Heart J. 2017;38:2910-2911.
    PubMed     Text format    


  20. PITT B, Rossignol P
    Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?
    Eur Heart J. 2017;38:2897-2899.
    PubMed     Text format    


  21. CHEN S, Dykes JC, McElhinney DB, Gajarski RJ, et al
    Haemodynamic profiles of children with end-stage heart failure.
    Eur Heart J. 2017;38:2900-2909.
    PubMed     Text format     Abstract available


  22. ALDAHL M, Jensen AC, Davidsen L, Eriksen MA, et al
    Associations of serum potassium levels with mortality in chronic heart failure patients.
    Eur Heart J. 2017;38:2890-2896.
    PubMed     Text format     Abstract available


    August 2017
  23. FITCHETT D, Butler J, van de Borne P, Zinman B, et al
    Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial.
    Eur Heart J. 2017 Aug 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. LUSCHER TF
    Update on heart failure: biomarkers, intensive therapy, remote monitoring, and cardiomyocyte renewal.
    Eur Heart J. 2017;38:2315-2317.
    PubMed     Text format    


  25. DE BOER RA, Meems LMG, van Veldhuisen DJ
    Vitamin D supplementation in heart failure: case closed?
    Eur Heart J. 2017;38:2287-2289.
    PubMed     Text format    


    July 2017
  26. GOLIASCH G, Bartko PE, Pavo N, Neuhold S, et al
    Refining the prognostic impact of functional mitral regurgitation in chronic heart failure.
    Eur Heart J. 2017 Jul 25. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  27. LUSCHER TF
    Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition.
    Eur Heart J. 2017;38:1857-1860.
    PubMed     Text format    


  28. ROURA S, Galvez-Monton C, Lupon J, Bayes-Genis A, et al
    Biotherapies and biomarkers for cardiovascular diseases: A 15-year journey at the ICREC (Heart Failure and Cardiac Regeneration) Research Laboratory in Barcelona, Spain.
    Eur Heart J. 2017;38:1784-1786.
    PubMed     Text format    


  29. CHATTERJEE NA, Singh JP
    Making sense of remote monitoring studies in heart failure.
    Eur Heart J. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format    


  30. SUGIHARA S, Burnett JC Jr
    BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?
    Eur Heart J. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format    


    May 2017
  31. MORGAN JM, Kitt S, Gill J, McComb JM, et al
    Remote management of heart failure using implantable electronic devices.
    Eur Heart J. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. SCUFFHAM PA, Ball J, Horowitz JD, Wong C, et al
    Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.
    Eur Heart J. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. ZITTERMANN A, Ernst JB, Prokop S, Fuchs U, et al
    Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.
    Eur Heart J. 2017 May 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. SCHUPKE S, Mehilli J
    Less myocardial scar but greater propensity for heart failure: another gender paradox in myocardial infarction.
    Eur Heart J. 2017 May 5. doi: 10.1093.
    PubMed     Text format    


    April 2017
  35. PANG PS, Butler J, Collins SP, Cotter G, et al
    Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).
    Eur Heart J. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. BORLAUG BA, Obokata M
    Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.
    Eur Heart J. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format    


  37. LUSCHER TF
    From systemic and pulmonary hypertension to heart failure: novel drugs and devices.
    Eur Heart J. 2017;38:1087-1090.
    PubMed     Text format    


  38. CLELAND JGF, Mueller C
    What can we learn from SOCRATES: more questions than answers?
    Eur Heart J. 2017;38:1128-1131.
    PubMed     Text format    


  39. MCDIARMID AK, Pellicori P, Cleland JG, Plein S, et al
    Taxonomy of segmental myocardial systolic dysfunction.
    Eur Heart J. 2017;38:942-954.
    PubMed     Text format     Abstract available


    March 2017
  40. PIESKE B, Maggioni AP, Lam CS, Pieske-Kraigher E, et al
    Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Eur Heart J. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. MCCULLOUGH PA, Rios A, Smith B
    Dialysis fistulas and heart failure.
    Eur Heart J. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format    


  42. OUWERKERK W, Voors AA, Anker SD, Cleland JG, et al
    Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
    Eur Heart J. 2017 Mar 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. LUSCHER TF
    Frontiers in heart failure: sodium, longitudinal strain, contractility sensor, fatal arrhythmias, and stroke.
    Eur Heart J. 2017;38:693-696.
    PubMed     Text format    


  44. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available


  45. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
    Eur Heart J. 2017;38:720-726.
    PubMed     Text format     Abstract available


    February 2017

  46. Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction [Eur Heart J 2017; doi:10.1093/eurheartj/ehx014].
    Eur Heart J. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format    


  47. MULLENS W, Verbrugge FH, Nijst P, Tang WH, et al
    Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.
    Eur Heart J. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. MATHUR A, Fernandez-Aviles F, Dimmeler S, Hauskeller C, et al
    The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    


  49. BAYES-GENIS A, Voors AA, Zannad F, Januzzi JL, et al
    Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    


  50. BOHM M, Young R, Jhund PS, Solomon SD, et al
    Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Eur Heart J. 2017 Feb 1. doi: 10.1093.
    PubMed     Text format    


  51. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
    Agents with vasodilator properties in acute heart failure.
    Eur Heart J. 2017;38:317-325.
    PubMed     Text format    


  52. LUSCHER TF
    An update on heart failure: from experimental findings to clinical trials.
    Eur Heart J. 2017;38:305-307.
    PubMed     Text format    


  53. TOFIELD A
    Teenage weight and risk for adult heart failure.
    Eur Heart J. 2017;38:311-312.
    PubMed     Text format    


  54. TOFIELD A
    End of the road for aliskiren in heart failure.
    Eur Heart J. 2017;38:312-313.
    PubMed     Text format    



  55. Professor Jay Cohn a pioneer in heart failure.
    Eur Heart J. 2017;38:308-309.
    PubMed     Text format    


  56. HARPER AR, Cowie MR
    Remote monitoring for heart failure: the story moves on.
    Eur Heart J. 2017;38:310-311.
    PubMed     Text format    


    January 2017
  57. BRUNO RM, Taddei S
    Sacubril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
    Eur Heart J. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format    


  58. LANDIN AM, Hare JM
    The quest for a successful cell-based therapeutic approach for heart failure.
    Eur Heart J. 2017 Jan 10. pii: ehw626. doi: 10.1093.
    PubMed     Text format    


  59. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
    Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
    Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
    PubMed     Text format    


  60. MAGGIONI AP, Ruschitzka F
    The year in cardiology 2016: heart failure.
    Eur Heart J. 2017 Jan 2. pii: ehw638. doi: 10.1093.
    PubMed     Text format    


    December 2016
  61. MAISEL AS, Di Somma S
    Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).
    Eur Heart J. 2016 Dec 27. pii: ehw462. doi: 10.1093.
    PubMed     Text format    


  62. NAKAMURA T, Masumoto A, Tahara N, Kuroda Y, et al
    Acute heart failure caused by mechanical valve leaflet dislodgment at the mitral position.
    Eur Heart J. 2016 Dec 23. pii: ehw521. doi: 10.1093.
    PubMed     Text format    


  63. BARTUNEK J, Terzic A, Davison BA, Filippatos GS, et al
    Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
    Eur Heart J. 2016 Dec 23. pii: ehw543. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. HOEPER MM, Lam CS, Vachiery JL, Bauersachs J, et al
    Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchdagger.
    Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093.
    PubMed     Text format    


  65. MINOIA C, Paolillo S
    Two weeks at Harvard, for two European heart failure trainees.
    Eur Heart J. 2016;37:3553-3554.
    PubMed     Text format    


  66. PAOLILLO S
    The ESC Heart Failure Association postgraduate course in heart failure.
    Eur Heart J. 2016;37:3551-3552.
    PubMed     Text format    


    November 2016
  67. AMMIRATI E, Burns JC, Moreo A, Daniels LB, et al
    Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease.
    Eur Heart J. 2016.
    PubMed     Text format    



  68. What the Heart Failure Congress means to the Heart Failure Association.
    Eur Heart J. 2016;37:3124-3126.
    PubMed     Text format    



  69. First European advice launched for acute heart failure.
    Eur Heart J. 2016;37:3123-3124.
    PubMed     Text format    



  70. What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?
    Eur Heart J. 2016;37:3121-3122.
    PubMed     Text format    


    October 2016
  71. CREA F, Bairey Merz CN, Beltrame JF, Kaski JC, et al
    The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift.
    Eur Heart J. 2016.
    PubMed     Text format    


  72. DOCHERTY KF, Campbell RT, Jhund PS, Petrie MC, et al
    How robust are clinical trials in heart failure?
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    September 2016
  73. JORGE C, Hiltrop N, Desmet W
    Heart failure with preserved ejection fraction: blame the veins....
    Eur Heart J. 2016.
    PubMed     Text format    


  74. MOHSENI H, Kiran A, Khorshidi R, Rahimi K, et al
    Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  75. JHUND PS
    Obesity and heart failure: when 'epidemics' collide.
    Eur Heart J. 2016 Sep 22. doi: 10.1093.
    PubMed     Text format    


  76. FRADLEY MG
    The evolving field of cardio-oncology: beyond anthracyclines and heart failure.
    Eur Heart J. 2016;37:2740-2742.
    PubMed     Text format    


  77. ZHABYEYEV P, Oudit GY
    Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.
    Eur Heart J. 2016.
    PubMed     Text format    


  78. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
    Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
    Eur Heart J. 2016.
    PubMed     Text format    



  79. The Acute Heart Failure Academy.
    Eur Heart J. 2016;37:2568-9.
    PubMed     Text format    


  80. LUSCHER TF
    From heart failure to transplantation: genes, miRNAs, and biomarkers.
    Eur Heart J. 2016;37:2561-3.
    PubMed     Text format    


    August 2016
  81. HADDAD S, Wang Y, Galy B, Korf-Klingebiel M, et al
    Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  82. LAM CS, Teng TK, Tay WT, Anand I, et al
    Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    July 2016
  83. ZANNAD F, Ferreira JP
    Globalization of heart failure trials: no turning back on this paradigm.
    Eur Heart J. 2016.
    PubMed     Text format    


  84. LUSCHER TF
    Breaking news in heart failure: ESC Guidelines 2016, non-steroidal mineralocorticoid receptor antagonist, and alternate site CRT pacing.
    Eur Heart J. 2016;37:2085-7.
    PubMed     Text format    


  85. HINDRICKS G, Varma N
    Remote monitoring and heart failure: monitoring parameters, technology, and workflow.
    Eur Heart J. 2016.
    PubMed     Text format    


    June 2016
  86. KRISTENSEN SL, Martinez F, Jhund PS, Arango JL, et al
    Geographic variations in the PARADIGM-HF heart failure trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  87. VON ROEDER M, Rommel KP, Blazek S, Daehnert I, et al
    Pressure-volume-loop-guided closure of an iatrogenic atrial septal defect for right heart failure following MitraClip-implantation.
    Eur Heart J. 2016.
    PubMed     Text format    


  88. EPSTEIN M, Pitt BC
    A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden frui
    Eur Heart J. 2016.
    PubMed     Text format    


  89. BORLAUG BA, Kane GC, Melenovsky V, Olson TP, et al
    Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  90. ROSENGREN A, Aberg M, Robertson J, Waern M, et al
    Body weight in adolescence and long-term risk of early heart failure in adulthood among men in Sweden.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  91. LUSCHER TF
    Frontiers in heart failure: assessement, risk factors, and novel genetic and cell-based therapies.
    Eur Heart J. 2016;37:1629-32.
    PubMed     Text format    


  92. FERREIRA JP, Girerd N, Alshalash S, Konstam MA, et al
    Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    May 2016
  93. PONIKOWSKI P, Voors AA, Anker SD, Bueno H, et al
    2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contributio
    Eur Heart J. 2016.
    PubMed     Text format    


  94. ANTMAN EM, Bax J, Chazal RA, Creager MA, et al
    Updated Clinical Practice Guidelines on Heart Failure: An International Alignment.
    Eur Heart J. 2016.
    PubMed     Text format    


  95. LUSCHER TF
    Frontiers in congenital heart disease: pulmonary hypertension, heart failure, and arrhythmias.
    Eur Heart J. 2016;37:1407-9.
    PubMed     Text format    


    April 2016
  96. NAEGELE M, Hernandez AF, Ruschitzka F
    Finerenone in heart failure: walking a fine line.
    Eur Heart J. 2016.
    PubMed     Text format    


  97. FILIPPATOS G, Anker SD, Bohm M, Gheorghiade M, et al
    A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  98. ARAS MA, Teerlink JR
    Lung ultrasound: a 'B-line' to the prediction of decompensated heart failure.
    Eur Heart J. 2016;37:1252-4.
    PubMed     Text format    


  99. LUSCHER TF
    Imaging as a basis of clinical decision-making in congenital and coronary disease and heart failure.
    Eur Heart J. 2016;37:1171-3.
    PubMed     Text format    


  100. SMISETH OA, Torp H, Opdahl A, Haugaa KH, et al
    Myocardial strain imaging: how useful is it in clinical decision making?
    Eur Heart J. 2016;37:1196-207.
    PubMed     Text format     Abstract available


  101. PATIL NP, Weymann A, Popov AF, Simon AR, et al
    Chest X-ray in cardiac illness: a tale of four decades.
    Eur Heart J. 2016;37:1243.
    PubMed     Text format    


  102. DESAI AS, Jhund PS
    After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  103. BAHLS M, Felix SB
    Cachexia and right ventricular dysfunction in chronic heart failure: what is the chicken and what the egg?
    Eur Heart J. 2016.
    PubMed     Text format    


  104. SCHWARZL M, Ojeda F, Zeller T, Seiffert M, et al
    Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  105. MADONNA R, Van Laake LW, Davidson SM, Engel FB, et al
    Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  106. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
    Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Eur Heart J. 2016;37:1015-23.
    PubMed     Text format    


    March 2016
  107. LUSCHER TF
    Update on hypertension: target blood pressure, comorbidities, and outcome.
    Eur Heart J. 2016;37:921-3.
    PubMed     Text format    


  108. BOHM M, Drexler H, Oswald H, Rybak K, et al
    Fluid status telemedicine alerts for heart failure: a randomized controlled trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  109. AUER J, Wallner M, Windpessl M, Schmidt WM, et al
    Acute decompensated heart failure associated with a heteroplasmic 3243A>G mitochondrial DNA point mutation.
    Eur Heart J. 2016.
    PubMed     Text format    


  110. BRAUNWALD E
    Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
    Eur Heart J. 2016;37:745-6.
    PubMed     Text format    


    February 2016
  111. HULOT JS, Ishikawa K, Hajjar RJ
    Gene therapy for the treatment of heart failure: promise postponed.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  112. SWEDBERG K, Ryden L
    Treatment of diabetes and heart failure: joint forces.
    Eur Heart J. 2016.
    PubMed     Text format    


  113. LOCH A, Geh DJ, Veriah RS
    Cardiac magnetic resonance imaging: a tool to diagnose parasitic infection?
    Eur Heart J. 2016;37:702.
    PubMed     Text format    


  114. VALENTOVA M, von Haehling S, Bauditz J, Doehner W, et al
    Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  115. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
    Agents with vasodilator properties in acute heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  116. LUSCHER TF
    Heart failure and left ventricular remodelling in HFrEF and HFpEF.
    Eur Heart J. 2016;37:423-4.
    PubMed     Text format    


  117. STROMBERG A, Wodlin P
    CardioPulse; Pocket-sized ultrasound for nurses in heart failure?
    Eur Heart J. 2016;37:434-5.
    PubMed     Text format    


  118. TCHAMBAZ L
    CardioPulse: The second Postgraduate Course in Heart Failure: 2016-2017.
    Eur Heart J. 2016;37:430-1.
    PubMed     Text format    


  119. BORLAUG BA
    Defining HFpEF: where do we draw the line?
    Eur Heart J. 2016;37:463-5.
    PubMed     Text format    


  120. DWECK M, Chin C
    CardioPulse: Settling scores with a failing heart.
    Eur Heart J. 2016;37:433-4.
    PubMed     Text format    


  121. WESTENBRINK BD, van Laake LW, Brugts JJ
    CardioPulse: The Postgraduate Course in Heart Failure.
    Eur Heart J. 2016;37:428-9.
    PubMed     Text format    


  122. DIMARCO A, Mansoubi H, Tanner M
    An unusual cause of left ventricular hypertrophy.
    Eur Heart J. 2016;37:497.
    PubMed     Text format    


  123. LECLERCQ C, Sadoul N, Mont L, Defaye P, et al
    Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.
    Eur Heart J. 2016;37:473-83.
    PubMed     Text format     Abstract available


  124. STONE GW, Chung ES, Stancak B, Svendsen JH, et al
    Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.
    Eur Heart J. 2016;37:484-93.
    PubMed     Text format     Abstract available


    January 2016
  125. FITCHETT D, Zinman B, Wanner C, Lachin JM, et al
    Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  126. PLATZ E, Lewis EF, Uno H, Peck J, et al
    Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patientsdagger.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  127. WANG K, Long B, Liu F, Wang JX, et al
    A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  128. RABER L, Piccolo R
    CardioPulse: Different bleeding scores and which one should we use?
    Eur Heart J. 2016;37:327-31.
    PubMed     Text format    


  129. BUDTS W, Roos-Hesselink J, Radle-Hurst T, Eicken A, et al
    Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.
    Eur Heart J. 2016.
    PubMed     Text format    


  130. NICHOLLS M
    CardioPulse: Cyclosporine to reduce myocardial infarction injury?
    Eur Heart J. 2016;37:210-1.
    PubMed     Text format    


  131. KOMAJDA M, Ruschitzka F
    The year in cardiology 2015: heart failure.
    Eur Heart J. 2016.
    PubMed     Text format    


    December 2015
  132. IUNG B, Doco-Lecompte T, Chocron S, Strady C, et al
    Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  133. HIGASHI H, Inaba S, Izutani H, Sumimoto T, et al
    An unusual cause of life-threatening right-sided heart failure: undifferentiated pleomorphic sarcoma in the right ventricular outflow tract.
    Eur Heart J. 2015.
    PubMed     Text format    


    November 2015
  134. PULS M, Lubos E, Boekstegers P, von Bardeleben RS, et al
    One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  135. OLDENBURG O, Wellmann B, Buchholz A, Bitter T, et al
    Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  136. LUSCHER TF
    Infections, infarction, and heart failure: prevention and management.
    Eur Heart J. 2015;36:3033-5.
    PubMed     Text format    


  137. MCMURRAY JJ
    Improving outcomes in heart failure: a personal perspectivedagger.
    Eur Heart J. 2015.
    PubMed     Text format    


  138. SKOURI H, Dickstein K
    Heart failure in the Middle East An Emerging Challenge in a Diverse Environment.
    Eur Heart J. 2015;36:2970-2.
    PubMed     Text format    


  139. VAN VELDHUISEN DJ, Ruilope LM, Maisel AS, Damman K, et al
    Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  140. WANG N, Hung CL, Shin SH, Claggett B, et al
    Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    October 2015
  141. ROSENKRANZ S, Gibbs JS, Wachter R, De Marco T, et al
    Left ventricular heart failure and pulmonary hypertensiondagger.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  142. KATZ AM, Rolett EL
    Heart failure: when form fails to follow function.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    September 2015
  143. KOTECHA D, Piccini JP
    Atrial fibrillation in heart failure: what should we do?
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  144. KASTRUP J
    Revival of cytokine therapy in heart failure?
    Eur Heart J. 2015.
    PubMed     Text format    


  145. CIKES M, Solomon SD
    Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  146. FRANCIS GS, Thenappan T
    Beta-blockers in heart failure: do we finally have the last word?
    Eur Heart J. 2015.
    PubMed     Text format    


  147. SOLOMON SD, Claggett B, Lewis EF, Desai A, et al
    Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  148. NICHOLLS M
    Research providing new insights into myocardial infarction injury.
    Eur Heart J. 2015;36:2345-6.
    PubMed     Text format    


  149. LUSCHER TF
    Risk factors for and management of heart failure.
    Eur Heart J. 2015;36:2267-9.
    PubMed     Text format    


    August 2015
  150. GORCSAN J 3RD, Sogaard P, Bax JJ, Singh JP, et al
    Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  151. MALASA M, Werner N, Nickenig G, Hammerstingl C, et al
    Transcatheter tricuspid valve repair in a patient with isolated functional tricuspid valve regurgitation.
    Eur Heart J. 2015.
    PubMed     Text format    


  152. GORCSAN J 3RD, Schwartzman D
    Ventricular arrhythmias after cardiac resynchronization therapy: does reverse remodelling reverse risk?
    Eur Heart J. 2015.
    PubMed     Text format    


  153. LUSCHER TF
    Prevention of non-communicable diseases and special causes of heart failure.
    Eur Heart J. 2015;36:2019-2022.
    PubMed     Text format    


  154. CHATTERJEE NA, Roka A, Lubitz SA, Gold MR, et al
    Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  155. LUSCHER TF
    Novel aspects of heart failure: from combined neurohormal blockade to embryonic stem cells.
    Eur Heart J. 2015;36:1937-9.
    PubMed     Text format    


  156. TAYLOR J
    Depression associated with five-fold increased mortality risk in heart failure patients.
    Eur Heart J. 2015;36:1946.
    PubMed     Text format    


  157. TAYLOR J
    Cognitive impairment predicts worse outcome in heart failure.
    Eur Heart J. 2015;36:1945.
    PubMed     Text format    


  158. TOFIELD A
    Digoxin mortality in heart failure and atrial fibrillation.
    Eur Heart J. 2015;36:1944-5.
    PubMed     Text format    


  159. PERRONE-FILARDI P, Paolillo S, Costanzo P, Savarese G, et al
    The role of metabolic syndrome in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    July 2015
  160. GONZALEZ-LOPEZ E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, et al
    Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  161. CASTANO A, Bokhari S, Maurer MS
    Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format    


  162. CORRADO D, Wichter T, Link MS, Hauer R, et al
    Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
    Eur Heart J. 2015.
    PubMed     Text format    


  163. DICKSTEIN K
    Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues.
    Eur Heart J. 2015.
    PubMed     Text format    


  164. HOENDERMIS ES, Liu LC, Hummel YM, van der Meer P, et al
    Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  165. BORLAUG BA
    Taking aim at pulmonary hypertension in heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format    


  166. STONE GW, Adams DH, Abraham WT, Kappetein AP, et al
    Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  167. GUO J, Mihic A, Wu J, Zhang Y, et al
    Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  168. MUNZEL T, Gori T, Keaney JF Jr, Maack C, et al
    Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    June 2015
  169. FADINI GP, Avogaro A, Degli Esposti L, Russo P, et al
    Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  170. TOFIELD A
    Blood sugar levels in heart failure patients predict risk of early death, hospitalizations, and diabetes.
    Eur Heart J. 2015;36:1498-9.
    PubMed     Text format    


  171. GIRERD N, Collier T, Pocock S, Krum H, et al
    Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  172. FELKER GM
    Augmenting outcomes in patients with advanced heart failure.
    Eur Heart J. 2015.
    PubMed     Text format    


  173. YSSAP J, Lebreton G, Hoen B, Larifla L, et al
    Infected left ventricular thrombus revealing an unrecognized coronary dissection after blunt chest trauma, treated with emergency heart transplantation.
    Eur Heart J. 2015.
    PubMed     Text format    


  174. PARKER JD
    Therapeutic developments in the therapy of heart failure: lessons to be learned.
    Eur Heart J. 2015.
    PubMed     Text format    


  175. ANKER SD, Coats AJ, Cristian G, Dragomir D, et al
    A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  176. FANKHAUSER CD, Nietlispach F, Emmert MY, Maisano F, et al
    Antegrade valve embolization after transcatheter treatment for pure aortic regurgitation.
    Eur Heart J. 2015.
    PubMed     Text format    


  177. LUSCHER TF
    Heart failure and comorbidities: renal failure, diabetes, atrial fibrillation, and inflammation.
    Eur Heart J. 2015;36:1415-7.
    PubMed     Text format    


  178. EDNER M, Benson L, Dahlstrom U, Lund LH, et al
    Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  179. CHUNG ES, Miller L, Patel AN, Anderson RD, et al
    Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  180. AMSTEIN R, Luscher TF, Maisano F, Ruschitzka FT, et al
    The new postgraduate course in heart failure (PCHF): update on 1st PCHF and announcement of the 2nd PCHF. A project of the European Society of Cardiology Heart Failure Association, the ESC European Heart Academy, the Zurich Heart House and the Univers
    Eur Heart J. 2015;36:1354-5.
    PubMed     Text format    


    May 2015
  181. DESAI AS, McMurray JJ, Packer M, Swedberg K, et al
    Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  182. MEBAZAA A, Yilmaz MB, Levy P, Ponikowski P, et al
    Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Em
    Eur Heart J. 2015.
    PubMed     Text format    


  183. MENASCHE P, Vanneaux V, Hagege A, Bel A, et al
    Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  184. FLORAS JS, Ponikowski P
    The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  185. SLIWA K, Johnson MR, Zilla P, Roos-Hesselink JW, et al
    Management of valvular disease in pregnancy: a global perspective.
    Eur Heart J. 2015;36:1078-89.
    PubMed     Text format     Abstract available


  186. HILFIKER-KLEINER D, Haghikia A, Nonhoff J, Bauersachs J, et al
    Peripartum cardiomyopathy: current management and future perspectives.
    Eur Heart J. 2015;36:1090-7.
    PubMed     Text format     Abstract available


  187. BUCKLEY U, Shivkumar K
    Implantable cardioverter defibrillators: even better than we thought?
    Eur Heart J. 2015.
    PubMed     Text format    


    April 2015
  188. RAPHAEL CE, Finegold JA, Barron AJ, Whinnett ZI, et al
    The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  189. SOLOMON S, Goncalves A
    CardioPulse: drinking moderate amounts of alcohol is linked to reduced risk of heart failure.
    Eur Heart J. 2015;36:890-1.
    PubMed     Text format    


  190. CONEN D
    Alcohol consumption and incident cardiovascular disease: not just one unifying hypothesis.
    Eur Heart J. 2015;36:897-8.
    PubMed     Text format    



  191. Stem cells for heart failure: the experience of writing a Cochrane systematic review.
    Eur Heart J. 2015;36:834-6.
    PubMed     Text format    


  192. HILFIKER-KLEINER D, Westhoff-Bleck M, Gunter HH, von Kaisenberg CS, et al
    A management algorithm for acute heart failure in pregnancy. The Hannover experience.
    Eur Heart J. 2015;36:769-70.
    PubMed     Text format    


    March 2015
  193. AMINZADEH MA, Tseliou E, Sun B, Cheng K, et al
    Therapeutic efficacy of cardiosphere-derived cells in a transgenic mouse model of non-ischaemic dilated cardiomyopathy.
    Eur Heart J. 2015;36:751-62.
    PubMed     Text format     Abstract available


  194. SAVVATIS K, Schultheiss HP, Tschope C
    Endomyocardial biopsy and ultrastructural changes in dilated cardiomyopathy: taking a 'deeper' look into patients' prognosis.
    Eur Heart J. 2015;36:708-10.
    PubMed     Text format    


  195. NABETA T, Itatani K, Miyaji K, Ako J, et al
    Vortex flow energy loss reflects therapeutic effect in dilated cardiomyopathy.
    Eur Heart J. 2015;36:637.
    PubMed     Text format    


    February 2015
  196. CALIFF RM
    LCZ696: too good to be true?
    Eur Heart J. 2015;36:410-2.
    PubMed     Text format    


  197. LUBITZ SA, Singh JP
    Biventricular pacing: more is better!
    Eur Heart J. 2015;36:407-9.
    PubMed     Text format    


    January 2015
  198. BANYPERSAD SM, Fontana M, Maestrini V, Sado DM, et al
    T1 mapping and survival in systemic light-chain amyloidosis.
    Eur Heart J. 2015;36:244-51.
    PubMed     Text format     Abstract available


    September 2014
  199. MIZIA-STEC K, Wybraniec MT, Bochenek T, Gierlaszynska K, et al
    Fulminant variant of Loeffler disease mimicking arrhythmogenic right ventricular cardiomyopathy in the course of enterobiasis.
    Eur Heart J. 2014.
    PubMed     Text format    


  200. CLAEYS MJ
    High-sensitivity troponin: does it predict the shape of the iceberg underneath the surface?
    Eur Heart J. 2014;35:2273-5.
    PubMed     Text format    


  201. KAYE GC, Linker NJ, Marwick TH, Pollock L, et al
    Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    August 2014
  202. FERRARI R, Rizzo P
    The Notch pathway: a novel target for myocardial remodelling therapy?
    Eur Heart J. 2014;35:2140-5.
    PubMed     Text format     Abstract available


  203. NENSA F, Poeppel TD, Krings P, Schlosser T, et al
    Multiparametric assessment of myocarditis using simultaneous positron emission tomography/magnetic resonance imaging.
    Eur Heart J. 2014;35:2173.
    PubMed     Text format    


  204. RUWALD AC, Kutyifa V, Ruwald MH, Solomon S, et al
    The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    May 2014
  205. CHIN CW, Shah AS, McAllister DA, Joanna Cowell S, et al
    High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: